This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
AbbVie (ABBV) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $117.63, moving +0.9% from the previous trading session.
3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season (Revised)
by Kinjel Shah
AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.
Lilly's (LLY) Jardiance Heart Failure Study Meets Main Goal
by Zacks Equity Research
Lilly's (LLY) Jardiance significantly reduces the risk of the composite of cardiovascular death or hospitalization for heart failure in patients with heart failure with preserved ejection fraction.
3 Big Drugmakers to Buy Ahead of the Q2 Earnings Season
by Kinjel Shah
AstraZeneca (AZN), AbbVie (ABBV) and Bayer (BAYRY) are three large drug sector companies worth buying now.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $115.17 in the latest trading session, marking a +0.8% move from the prior day.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
ABBV vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
ABBV vs. NVO: Which Stock Is the Better Value Option?
Is AbbVie (ABBV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
Pharma Stock Roundup: EU Nod to RHHBY, MRK Drugs, FDA and Pipeline Updates
by Kinjel Shah
EU approves Roche's (RHHBY) Enspryng and Merck's (MRK) Keytruda for a new indication. FDA grants EUA to Roche's Actemra for COVID-19.
Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck
by Zacks Equity Research
Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $113 in the latest trading session, marking a +0.02% move from the prior day.
AbbVie's (ABBV) Rinvoq sNDA Decision Delayed by the FDA
by Zacks Equity Research
The FDA will not meet its action dates for AbbVie's (ABBV) sNDAs for JAK inhibitor drug, Rinvoq (upadacitinib), for active psoriatic arthritis and active ankylosing spondylitis in adults.
Editas (EDIT) Begins Enrollment in Kids Arm of Gene Drug Study
by Zacks Equity Research
Editas (EDIT) starts enrollment of the first pediatric cohort in the phase I/II BRILLIANCE study on EDIT-101 for treating Leber congenital amaurosis 10 (LCA10). Stock up.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $114.73 in the latest trading session, marking a +1.42% move from the prior day.
Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal
by Zacks Equity Research
Aprea (APRE) announces that treatment with a combination regimen of its pipeline candidate, eprenetapopt, achieves 37% complete response rate in acute myeloid leukemia patients.
Why AbbVie (ABBV) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $115.40, marking a -0.02% move from the previous day.
Incyte's (INCY) sNDA Review for Jakafi in GVHD Gets Extended
by Zacks Equity Research
Incyte's (INCY) sNDA review of Jakafi for the indication of steroid-refractory chronic GVHD gets extended by three months.
argenx (ARGX) to Regain AML Candidate After J&J's Dismissal
by Zacks Equity Research
argenx (ARGX) is developing cusatuzumab as potential treatment for acute myeloid leukemia. However, its partner, J&J, decided to discontinue the development agreement with the company for the candidate.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $113.01 in the latest trading session, marking a +0.58% move from the prior day.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Maintenance Study
by Zacks Equity Research
AbbVie (ABBV) is focusing on label expansion of Skyrizi beyond plaque psoriasis. The drug achieves endoscopic response and clinical remission as maintenance treatment for Crohn's disease study.
Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved
by Zacks Equity Research
The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up
Amgen (AMGN) Inks Deal With Kyowa Kirin to Develop AD Treatment
by Zacks Equity Research
Amgen (AMGN) inks an agreement with Kyowa Kirin Co. to develop and commercialize the latter's KHK4083, which is being developed for the treatment of atopic dermatitis.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.